Hyperpolarized Pyruvate (13C) MR Imaging in Monitoring Patients With Prostate Cancer on Active Surveillance

Eligibility Criteria

• * The subject has biopsy-proven adenocarcinoma of the prostate with low to intermediate risk disease by UCSF-CAPRA scoring at study entry.
• * For Part 1: Patient planning to enroll or currently on active surveillance; For Part 2: Currently enrolled on active surveillance with planned fusion biopsy within 12 weeks following completion of baseline HP C-13 pyruvate/mpMRI on study.
• * The subject is able and willing to comply with study procedures and provide signed and dated informed consent.
• * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
• * Absolute neutrophil count (ANC) \>= 1000 cells/microliter (uL).
• * Hemoglobin \>= 9.0 gm/deciliter (dL).
• * Platelets \>= 75,000 cells/uL.
• * Estimated creatinine clearance\* \>= 50 milliliter (mL)/min by the Cockcroft Gault equation.
• * Total bilirubin =\< 1.5 x upper limit of normal (ULN) or if =\< 3 x ULN if known/suspected Gilbert's
• * Aspartate aminotransferase (AST) =\< 1.5 x ULN.
• * Alanine aminotransferase (ALT) =\< 1.5 x ULN.
• * Patients without evidence of any prostate cancer on most recent prostate biopsy performed prior to study entry.
• * Current or prior androgen deprivation therapy including luteinizing hormone-releasing hormone (LHRH) analogue or oral anti-androgen therapy. Previous use of a 5-alpha reductase inhibitor is allowed, provided it was discontinued at least 28 days prior to baseline C-13 HP pyruvate MRI
• * Prior radiation treatment of the prostate.
• * Prostate biopsy performed within 14 days prior to baseline C-13 HP pyruvate MRI.
• * Poorly controlled hypertension, with blood pressure at study entry \> 160 mm Hg systolic or \> 100 mmg Hg diastolic. Treatment with anti-hypertensives and re-screening is permitted.
• * Congestive heart failure with New York Heart Association (NYHA) status \>= 2.